Angermeyer believes that over the next 10-20 years longevity will be the centerpoint of health research.  The longevity market is 100% of the population, and many of his rich friends would spend all of their money for extra years of quality life.  Rejuveron, Angermeyer’s company, will only be one of a whole sector of companies focused on aging.  Having a diverse portfolio of companies allows for cross pollination of ideas.  

 

Aging should be considered a disease.  In the meantime, targeting standard diseases alongside aging is a good strategy.  Having reliable biomarkers continues to be one of the top priorities in the near-term for moving aging into the clinical space.  Rejuveron currently operates in clinical and preclinical areas.  Translating aging research is difficult because amazing scientists are often not amazing drug development people.

 

Angermeyer also spoke on neurotech, climate change, and cryptocurrency.